- Mechanism
- Stimulates satellite cell proliferation via MEK-ERK pathway
- Typical research dose
- 100-200 mcg localized (research)
- Route
- intramuscular, subcutaneous
- Half-life
- Minutes (Natural) / 48-72 hours (PEGylated)
- Legal status
- Research Only, WADA Prohibited
Overview
MGF (Mechano Growth Factor) is an endogenous splice variant of insulin-like growth factor-1 (IGF-1) that is locally expressed in skeletal muscle following mechanical stress or damage. The MGF peptide plays a critical role in tissue repair by activating muscle satellite cells, which are essential for hypertrophy and regeneration. Research indicates that it acts as a localized signaling molecule to initiate the early phases of muscle healing before systemic IGF-1 takes over. Understanding MGF matters because its targeted action offers significant potential for treating muscle wasting diseases, severe injuries, and age-related sarcopenia.
Potential Benefits
- Satellite Cell Activation: The MGF peptide stimulates the proliferation of mononucleated myoblasts, which is the crucial first step in repairing damaged muscle fibers (Goldspink, 2005).
- Muscle Hypertrophy: By increasing the local pool of satellite cells, MGF provides the necessary nuclei for muscle fibers to grow and adapt to mechanical overload.
- Neuroprotection: Studies suggest MGF exhibits neuroprotective properties, potentially preventing motor neuron loss in conditions like ALS or following ischemic injury.
- Cartilage and Bone Repair: MGF has been shown to promote the migration and proliferation of chondrocytes and osteoblasts, accelerating the healing of skeletal injuries.
- Prevention of Sarcopenia: Exogenous administration of MGF may counteract age-related muscle loss by restoring the diminished local regenerative response seen in older adults.
- Cardiac Tissue Regeneration: Research indicates MGF is upregulated in the heart following myocardial infarction, where it helps protect cardiac muscle cells from apoptosis.
Side Effects
Common side effects:
- Injection site redness or irritation
- Mild fluid retention
- Temporary localized swelling
- Hypoglycemia (if systemic absorption occurs)
- Fatigue
Rare or serious side effects:
- Unregulated cellular proliferation
- Cardiovascular hypertrophy (with chronic high dosing)
- Severe hypoglycemic episodes
- Potential exacerbation of existing neoplasms
MGF is not FDA-approved and is intended for research purposes only. Consult a qualified healthcare provider before use.
Mechanism of Action
Mechanical transduction triggers the alternative splicing of the IGF-1 gene, producing the MGF peptide (IGF-1Ec in humans) in response to muscle stretch or damage. Unlike systemic IGF-1, MGF contains a unique 24-amino acid C-terminal peptide sequence that acts independently of the standard IGF-1 receptor to stimulate satellite cell activation and proliferation. This localized burst of MGF expression lasts for a short duration, typically 24 to 48 hours post-injury, effectively kickstarting the regenerative process before the cells differentiate.
Cellular signaling pathways activated by MGF remain a subject of active investigation, but evidence points toward the involvement of the MEK-ERK pathway in promoting rapid cell division. Once the initial proliferation phase is complete, MGF expression naturally declines, allowing systemic IGF-1Ea to promote the differentiation and fusion of these newly formed myoblasts into mature muscle fibers. This sequential mechanism ensures that the muscle tissue first builds an adequate pool of precursor cells before committing them to structural repair.
Origin & History
Discovery of MGF occurred in the late 1990s when researcher Geoffrey Goldspink and his team identified a novel IGF-1 splice variant that was highly upregulated in rabbit skeletal muscle following mechanical stretch. They named it Mechano Growth Factor to distinguish its unique local action and distinct C-terminal domain from liver-derived systemic IGF-1. Subsequent research successfully isolated the human equivalent, IGF-1Ec, and synthesized the active C-terminal fragment to study its isolated effects in vitro and in vivo.
Regulatory status for the MGF peptide remains strictly limited to laboratory and preclinical research. The FDA has not approved MGF for human therapeutic use, and it is currently classified as a research-only compound. Due to its potent anabolic properties and ability to enhance muscle recovery, MGF is listed as a prohibited substance by the World Anti-Doping Agency (WADA). This restricts its use in competitive sports while clinical investigations continue into its therapeutic applications for severe muscular dystrophy, cachexia, and age-related sarcopenia.